close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

146.73 -0.21 (-0.14%)
Official Closing Price Updated: 7:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Moderna Just Gave Investors Yet Another Thing to Cheer About ↗
Moderna's cancer vaccine has been the big story this year, but its latest quarter showed the rest of its business is improving, too. 
Via The Motley Fool
News headline image
2 Growth Stocks to Buy in November Without Any Hesitation ↗
They have both outperformed the broader equity market over the long run. 
Via The Motley Fool
News headline image
History Says This ETF Is a Fantastic Buy-and-Hold Investment -- and It Could Turn $100 per Month Into $359,492 ↗
This dividend ETF has delivered surprisingly strong growth for the past 15 years. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
Dow Jones Losers on Nov. 3, 2026: SHW, HD and MRK Lead Declines ↗
Via Chartmill
Topics Stocks
Dow Jones Biggest Decliners in Today's US Session ↗
Via Chartmill
Topics Stocks
News headline image
Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success ↗
Even if the company's vaccine obtains approval, producing it at scale could be a big challenge. 
Via The Motley Fool
News headline image
3 Stocks That Did Well the Last Time the Fed Raised Rates Aggressively ↗
In 2022, the last time rates rose quickly, these stocks surged, a couple of them by more than 80%. 
Via The Motley Fool
Topics Economy
News headline image
Tempus AI Surges on Earnings Beat, But Can the Rally Last? ↗
Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside. 
Via MarketBeat
Topics Artificial Intelligence Earnings Initial Public Offering
Merck & Co. (NYSE:MRK) Posts Q3 Earnings Beat as EPS Surprise Offsets In-Line Sales Guidance ↗
Via Chartmill
Topics Earnings
Dow Jones Top Gainers in Today's Session: 3M Leads ↗
Via Chartmill
Topics Stocks
Dow Jones Top Gainers on Oct. 20, 2026: MMM, UNH, MRK Lead Session ↗
Via Chartmill
Topics Stocks
Merck (NYSE:MRK) Nears Breakout Setup With Strong Technical Ratings ↗
Via Chartmill
News headline image
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs ↗
The market for GLP-1 drugs is forecast to explode. It may be understated still. 
Via The Motley Fool
News headline image
Why Merck Stock Flew Higher on Friday ↗
Investors were still buying it in the afterglow of its latest quarterly earnings release. 
Via The Motley Fool
Topics Intellectual Property
News headline image
MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds
Global pharmaceutical company Merck (NYSE:MRK) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 4.7% year on year to $18.09 bil... 
Via StockStory
News headline image
Merck & Co., Inc. Q3 Earnings Call Highlights ↗
Merck & Co., Inc. (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% from a year earlier, as growth in oncology, vaccines, cardiometabolic products and animal health helped offset... 
Via MarketBeat
Topics Earnings
Dow Jones Top Movers for Oct. 29, 2026: Merck and Nike Lead Gainers, Alphabet and Caterpillar Fall ↗
Via Chartmill
Topics Stocks
News headline image
Merck (MRK) Q3 2026 Earnings Call Transcript ↗
Generic headwinds ahead in 2027, but new launches and WINREVAIR growth signal momentum. 
Via The Motley Fool
Topics Earnings
News headline image
Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings Reaction ↗
Merck’s new drugs are growing fast enough to cover generic losses, but part of this quarter’s sales gain won’t last. Here’s what to watch. 
Via The Motley Fool
Topics Intellectual Property
Dow Jones Top Movers Today: 8 Gainers, 4 Losers in Split Session ↗
Via Chartmill
Topics Stocks
News headline image
Merck (NYSE:MRK) delivers impressive Q3 2026
Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q3 2026, with revenue rising 4.7% year on year to $18.09 billion. Th... 
Via StockStory
News headline image
Could Revolution Medicines Be a Millionaire-Maker Stock? ↗
The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one. 
Via The Motley Fool
News headline image
Merck (MRK) reports Q3: everything you need to know ahead of earnings
Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday before market open. Here’s what investors should know. Merck beat ana... 
Via StockStory
Topics Artificial Intelligence
News headline image
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid? ↗
Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved. 
Via MarketBeat
News headline image
Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts ↗
Merck & Co., Inc. (NYSE:MRK) outlined new oncology data and development plans at the European Society for Medical Oncology annual meeting, highlighting phase III results for its sacituzumab... 
Via MarketBeat
S&P 500 Top Movers: Gainers and Losers in Today's US Session ↗
Via Chartmill
Topics Stocks
News headline image
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts ↗
MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach ↗
Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk. 
Via MarketBeat
News headline image
Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 ↗
The market has rewarded this biotech for its breakthroughs. 
Via The Motley Fool
News headline image
Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice ↗
This company made headlines with its coronavirus vaccine. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.